Argyrophilic grain disease as a neurodegenerative substrate in late-onset schizophrenia and delusional disorders

  • Shigeto Nagao
  • Osamu YokotaEmail author
  • Chikako Ikeda
  • Naoya Takeda
  • Hideki Ishizu
  • Shigetoshi Kuroda
  • Koichiro Sudo
  • Seishi Terada
  • Shigeo Murayama
  • Yosuke Uchitomi
Original Paper


To study the relationship between neurodegenerative diseases including argyrophilic grain disease (AGD) and late-onset schizophrenia and delusional disorders (LOSD; onset ≥40 years of age), we pathologically examined 23 patients with LOSD, 71 age-matched normal controls, and 22 psychiatric disease controls (11 depression, six personality disorder, two bipolar disorders, and three neurotic disorders cases). In all LOSD cases (compared to age-matched normal controls), the frequencies of Lewy body disease (LBD), AGD, and corticobasal degeneration (CBD) were 26.1 % (11.3 %), 21.7 % (8.5 %), and 4.3 % (0.0 %), respectively. There was no case of pure Alzheimer’s disease (AD). The total frequency of LBD, AGD, and CBD was significantly higher in LOSD cases than in normal controls. Argyrophilic grains were significantly more severe in LOSD than in controls, but were almost completely restricted to the limbic system and adjacent temporal cortex. In LOSD patients whose onset occurred at ≥65 years of age (versus age-matched normal controls), the frequencies of LBD and AGD were 36.4 % (19.4 %) and 36.4 % (8.3 %), respectively, and AGD was significantly more frequent in LOSD patients than in normal controls. In LOSD patients whose onset occurred at <65 years of age, the frequencies of LBD, AGD, and CBD were 16.7, 8.3, and 8.3 %, comparable to those of age-matched normal controls (10.2, 5.1, and 0.0 %). In all psychiatric cases, delusion was significantly more frequent in AGD cases than in cases bearing minimal AD pathology alone. Given these findings, LOSD patients may have heterogeneous pathological backgrounds, and AGD may be associated with the occurrence of LOSD especially after 65 years of age.


Argyrophilic grain α-Synuclein Corticobasal degeneration Four-repeat tau Late onset Tauopathy 



We would like to thank Ms. Onbe (Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences) for her excellent technical assistance. This work was supported in part by Grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology (Nos. 21591517, 23591708), and the Zikei Institute of Psychiatry.

Conflict of interest



  1. 1.
    Sadock BJ, Sadock VA (2003) Kaplan and Sadock’s synopsis of psychiatry: behavioral sciences/clinical psychiatry, 9th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  2. 2.
    American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, text revision (DSM-IV-TR), American Psychiatric Association, Washington DCGoogle Scholar
  3. 3.
    Bleuler M (1943) Late schizophrenic clinical pictures. Fortschr Neurol Psychiatr 15:259–290Google Scholar
  4. 4.
    Howard R, Castle D, Wessely S, Murray R (1993) A comparative study of 470 cases of early-onset and late-onset schizophrenia. Br J Psychiatry 163:352–357PubMedCrossRefGoogle Scholar
  5. 5.
    Howard R, Almeida O, Levy R (1994) Phenomenology, demography and diagnosis in late paraphrenia. Psychol Med 24:397–410PubMedCrossRefGoogle Scholar
  6. 6.
    Pearlson GD, Kreger L, Rabins PV, Chase GA, Cohen B, Wirth JB, Schlaepfer TB, Tune LE (1989) A chart review study of late-onset and early-onset schizophrenia. Am J Psychiatry 146:1568–1574PubMedGoogle Scholar
  7. 7.
    Rabins P, Pauker S, Thomas J (1984) Can schizophrenia begin after age 44? Compr Psychiatry 25:290–293PubMedCrossRefGoogle Scholar
  8. 8.
    Riecher-Rössler A, Löffler W, Munk-Jørgensen P (1997) What do we really know about late-onset schizophrenia? Eur Arch Psychiatry Clin Neurosci 247:195–208PubMedCrossRefGoogle Scholar
  9. 9.
    Rajji TK, Ismail Z, Mulsant BH (2009) Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry 195:286–293PubMedCrossRefGoogle Scholar
  10. 10.
    Howard R, Rabins PV, Seeman MV, Jeste DV (2000) Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry 157:172–178PubMedCrossRefGoogle Scholar
  11. 11.
    Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M (1997) ‘Vascular depression’ hypothesis. Arch Gen Psychiatry 54:915–922PubMedCrossRefGoogle Scholar
  12. 12.
    Fujikawa T, Yamawaki S, Touhouda Y (1993) Incidence of silent cerebral infarction in patients with major depression. Stroke 24:1631–1634PubMedCrossRefGoogle Scholar
  13. 13.
    Stewart R, Prince M, Mann A, Richards M, Brayne C (2001) Stroke, vascular risk factors and depression: cross-sectional study in a UK Caribbean-born population. Br J Psychiatry 178:23–28PubMedCrossRefGoogle Scholar
  14. 14.
    Thomas AJ, Ferrier IN, Kalaria RN, Perry RH, Brown A, O’Brien JT (2001) A neuropathological study of vascular factors in late-life depression. J Neurol Neurosurg Psychiatry 70:83–87PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Krishnan KR, McDonald WM, Doraiswamy PM, Tupler LA, Husain M, Boyko OB, Figiel GS, Ellinwood EH Jr (1993) Neuroanatomical substrates of depression in the elderly. Eur Arch Psychiatry Clin Neurosci 243:41–46PubMedCrossRefGoogle Scholar
  16. 16.
    Förstl H, Burns A, Luthert P, Cairns N, Lantos P, Levy R (1992) Clinical and neuropathological correlates of depression in Alzheimer’s disease. Psychol Med 22:877–884PubMedCrossRefGoogle Scholar
  17. 17.
    Gibb WR, Esiri MM, Lees AJ (1987) Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 110:1131–1153PubMedCrossRefGoogle Scholar
  18. 18.
    Klatka LA, Louis ED, Schiffer RB (1996) Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer’s disease and Parkinson’s disease comparison groups. Neurology 47:1148–1152PubMedCrossRefGoogle Scholar
  19. 19.
    Tsopelas C, Stewart R, Savva GM, Brayne C, Ince P, Thomas A, Matthews FE, Medical Research Council Cognitive Function and Ageing Study (2011) Neuropathological correlates of late-life depression in older people. Br J Psychiatry 198:109–114PubMedCrossRefGoogle Scholar
  20. 20.
    Xekardaki A, Santos M, Hof P, Kövari E, Bouras C, Giannakopoulos P (2012) Neuropathological substrates and structural changes in late-life depression: the impact of vascular burden. Acta Neuropathol 124:453–464PubMedCrossRefGoogle Scholar
  21. 21.
    Jellinger KA (2013) Organic bases of late-life depression: a critical update. J Neural Transm 120:1109–1125PubMedCrossRefGoogle Scholar
  22. 22.
    Jellinger KA, Gabriel E (1999) No increased incidence of Alzheimer’s disease in elderly schizophrenics. Acta Neuropathol 97:165–169PubMedCrossRefGoogle Scholar
  23. 23.
    Jellinger KA (2009) Lewy body/alpha-synucleinopathy in schizophrenia and depression: a preliminary neuropathological study. Acta Neuropathol 117:423–427PubMedCrossRefGoogle Scholar
  24. 24.
    Casanova MF, Stevens JR, Brown R, Royston C, Bruton C (2002) Disentangling the pathology of schizophrenia and paraphrenia. Acta Neuropathol 103:313–320PubMedCrossRefGoogle Scholar
  25. 25.
    Bozikas VP, Kövari E, Bouras C, Karavatos A (2002) Neurofibrillary tangles in elderly patients with late onset schizophrenia. Neurosci Lett 324:109–112PubMedCrossRefGoogle Scholar
  26. 26.
    Casanova MF (2003) Preservation of hippocampal pyramidal cells in paraphrenia. Schizophr Res 62:141–146PubMedCrossRefGoogle Scholar
  27. 27.
    Birkett DP, Desouky A, Han L, Kaufman M (1992) Lewy bodies in psychiatric patients. Int J Geriatr Psychiatry 7:235–240CrossRefGoogle Scholar
  28. 28.
    Aarsland D, Litvan I, Larsen JP (2001) Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13:42–49PubMedCrossRefGoogle Scholar
  29. 29.
    Geda YE, Boeve BF, Negash S, Graff-Radford NR, Knopman DS, Parisi JE, Dickson DW, Petersen RC (2007) Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. J Neuropsychiatry Clin Neurosci 19:77–80PubMedCrossRefGoogle Scholar
  30. 30.
    Josephs KA, Dickson DW (2003) Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 18:1018–1026PubMedCrossRefGoogle Scholar
  31. 31.
    Togo T, Isojima D, Akatsu H, Suzuki K, Uchikado H, Katsuse O, Iseki E, Kosaka K, Hirayasu Y (2005) Clinical features of argyrophilic grain disease: a retrospective survey of cases with neuropsychiatric symptoms. Am J Geriatr Psychiatry 13:1083–1091PubMedCrossRefGoogle Scholar
  32. 32.
    Braak H, Braak E (1998) Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm 105:801–819PubMedCrossRefGoogle Scholar
  33. 33.
    Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, Yamanouchi H, Murayama S (2004) Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 63:911–918PubMedGoogle Scholar
  34. 34.
    Asaoka T, Tsuchiya K, Fujishiro H, Arai T, Hasegawa M, Akiyama H, Iseki E, Oda T, Onaya M, Tominaga I (2010) Argyrophilic grain disease with delusions and hallucinations: a pathological study. Psychogeriatrics 10:69–76PubMedCrossRefGoogle Scholar
  35. 35.
    Ikeda K, Akiyama H, Arai T, Matsushita M, Tsuchiya K, Miyazaki H (2000) Clinical aspects of argyrophilic grain disease. Clin Neuropathol 19:278–284PubMedGoogle Scholar
  36. 36.
    Ishihara K, Araki S, Ihori N, Shiota J, Kawamura M, Yoshida M, Hashizume Y, Nakano I (2005) Argyrophilic grain disease presenting with frontotemporal dementia: a neuropsychological and pathological study of an autopsied case with presenile onset. Neuropathology 25:165–170PubMedCrossRefGoogle Scholar
  37. 37.
    Maurage CA, Sergeant N, Schraen-Maschke S, Lebert F, Ruchoux MM, Sablonnière B, Pasquier F, Delacourte A (2003) Diffuse form of argyrophilic grain disease: a new variant of four-repeat tauopathy different from limbic argyrophilic grain disease. Acta Neuropathol 106:575–583PubMedCrossRefGoogle Scholar
  38. 38.
    Tsuchiya K, Mitani K, Arai T, Yamada S, Komiya T, Esaki Y, Haga C, Yamanouchi H, Ikeda K (2001) Argyrophilic grain disease mimicking temporal Pick’s disease: a clinical, radiological, and pathological study of an autopsy case with a clinical course of 15 years. Acta Neuropathol 102:195–199PubMedCrossRefGoogle Scholar
  39. 39.
    Yokota O, Davidson Y, Bigio EH, Ishizu H, Terada S, Arai T, Hasegawa M, Akiyama H, Sikkink S, Pickering-Brown S, Mann DM (2010) Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol 120:55–66PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259PubMedCrossRefGoogle Scholar
  42. 42.
    Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMedCrossRefGoogle Scholar
  43. 43.
    The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. Neurobiol Aging 18(4 Suppl):S1–S2Google Scholar
  44. 44.
    Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT, National Institute on Aging, Alzheimer’s Association (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123:1–11PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRefGoogle Scholar
  46. 46.
    Uchikado H, Lin WL, DeLucia MW, Dickson DW (2006) Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 65:685–697PubMedCrossRefGoogle Scholar
  47. 47.
    Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan I, Office of Rare Diseases of the National Institutes of Health (2002) Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61:935–946PubMedGoogle Scholar
  48. 48.
    Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I (1994) Preliminary NINDS neuropathologic criteria for Steele–Richardson–Olszewski syndrome (progressive supranuclear palsy). Neurology 44:2015–2019PubMedCrossRefGoogle Scholar
  49. 49.
    Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 61:435–445PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Yokota O, Tsuchiya K, Terada S, Ishizu H, Uchikado H, Ikeda M, Oyanagi K, Nakano I, Murayama S, Kuroda S, Akiyama H (2008) Basophilic inclusion body disease and neuronal intermediate filament inclusion disease: a comparative clinicopathological study. Acta Neuropathol 115:561–575PubMedCrossRefGoogle Scholar
  51. 51.
    Yokota O, Tsuchiya K, Arai T, Yagishita S, Matsubara O, Mochizuki A, Tamaoka A, Kawamura M, Yoshida H, Terada S, Ishizu H, Kuroda S, Akiyama H (2009) Clinicopathological characterization of Pick’s disease versus frontotemporal lobar degeneration with ubiquitin/TDP-43-positive inclusions. Acta Neuropathol 117:429–444PubMedCrossRefGoogle Scholar
  52. 52.
    Kovacs GG, Majtenyi K, Spina S, Murrell JR, Gelpi E, Hoftberger R, Fraser G, Crowther RA, Goedert M, Budka H, Ghetti B (2008) White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. J Neuropathol Exp Neurol 67:963–975PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Yamada M (2003) Senile dementia of the neurofibrillary tangle type (tangle-only dementia): neuropathological criteria and clinical guidelines for diagnosis. Neuropathology 23:311–317PubMedCrossRefGoogle Scholar
  54. 54.
    Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T (2003) Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol 106:374–382PubMedCrossRefGoogle Scholar
  55. 55.
    Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70:960–969PubMedCrossRefGoogle Scholar
  56. 56.
    Cummings JL (1985) Organic delusions: phenomenology, anatomical correlations, and review. Br J Psychiatry 146:184–197PubMedCrossRefGoogle Scholar
  57. 57.
    Cummings JL, Mega MS (eds) (2003) Psychosis, delusion, and schizophrenia. In: Neuropsychiatry and behavioral neuroscience. Oxford University Press, New York, pp 172–186Google Scholar
  58. 58.
    McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK (1992) Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 22:911–922PubMedCrossRefGoogle Scholar
  59. 59.
    Aarsland D, Marsh L, Schrag A (2009) Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord 24:2175–2186PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Aarsland D, Ballard C, Larsen JP, McKeith I (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry 16:528–536PubMedCrossRefGoogle Scholar
  61. 61.
    Perneczky R, Drzezga A, Boecker H, Förstl H, Kurz A, Häussermann P (2008) Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations. Dement Geriatr Cogn Disord 25:531–538PubMedCrossRefGoogle Scholar
  62. 62.
    Jellinger KA (2012) Cerebral correlates of psychotic syndromes in neurodegenerative diseases. J Cell Mol Med 2012(16):995–1012CrossRefGoogle Scholar
  63. 63.
    Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRefGoogle Scholar
  64. 64.
    Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314–1322PubMedCrossRefGoogle Scholar
  65. 65.
    Diederich NJ, Leurgans S, Fan W, Chmura TA, Goetz CG (2008) Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry 23:598–603PubMedCrossRefGoogle Scholar
  66. 66.
    Yatabe Y, Hashimoto M, Kaneda K, Honda K, Ogawa Y, Yuuki S, Matsuzaki S, Tuyuguchi A, Kashiwagi H, Ikeda M (2011) Neuropsychiatric symptoms of progressive supranuclear palsy in a dementia clinic. Psychogeriatrics 11:54–59PubMedCrossRefGoogle Scholar
  67. 67.
    Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG (2011) α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10:230–240PubMedCrossRefGoogle Scholar
  68. 68.
    Luk C, Compta Y, Magdalinou N, Martí MJ, Hondhamuni G, Zetterberg H, Blennow K, Constantinescu R, Pijnenburg Y, Mollenhauer B, Trenkwalder C, Van Swieten J, Chiu WZ, Borroni B, Cámara A, Cheshire P, Williams DR, Lees AJ, de Silva R (2012) Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem 123:396–405PubMedCrossRefGoogle Scholar
  69. 69.
    Foulds PG, Yokota O, Thurston A, Davidson Y, Ahmed Z, Holton J, Thompson JC, Akiyama H, Arai T, Hasegawa M, Gerhard A, Allsop D, Mann DM (2012) Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson’s disease and Dementia with Lewy bodies. Neurobiol Dis 45:188–195PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Shigeto Nagao
    • 1
  • Osamu Yokota
    • 1
    Email author
  • Chikako Ikeda
    • 1
  • Naoya Takeda
    • 1
  • Hideki Ishizu
    • 1
    • 2
  • Shigetoshi Kuroda
    • 2
  • Koichiro Sudo
    • 3
  • Seishi Terada
    • 1
  • Shigeo Murayama
    • 4
  • Yosuke Uchitomi
    • 1
  1. 1.Department of NeuropsychiatryOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesKita-kuJapan
  2. 2.Zikei Institute of PsychiatryMinami-kuJapan
  3. 3.Department of PsychiatryTosa HospitalKochiJapan
  4. 4.Department of NeuropathologyTokyo Metropolitan Geriatric Hospital and Institute of GerontologyTokyoJapan

Personalised recommendations